Guo Honggang, Cui Yabin, Bai Yanliang, Yan Fan, Zhang Wenhui, Chen Yuqing, Shi Mingyue
Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, People's Republic of China.
Department of Hematology, Henan University People's Hospital, Zhengzhou, People's Republic of China.
Int J Gen Med. 2024 Jul 8;17:2967-2979. doi: 10.2147/IJGM.S466364. eCollection 2024.
Relapsed/refractory acute myeloid leukemia (R/R-AML) has dismal prognosis due to chemotherapy resistance. Circular RNAs (circRNAs) have shown emerging roles in chemotherapy resistance in various cancers including hematologic malignancies. However, the potential roles of circRNAs in AML progression and drug resistance remain largely undetermined.
In this study, circulating circRNAs expression profiles were analyzed among R/R-AML, AML and healthy controls (HC) using a human circRNA Array. Bioinformatic analysis was carried out to explore the differentially expressed circRNAs (DE-circRNAs). GO, KEGG pathway analysis, along with circRNA-miRNA-mRNA network analysis, were conducted to identify the potential biological pathways involved in R/R-AML. Finally, the UALCAN database was used to assess the prognosis of different target DE-circRNAs-related mRNAs.
Forty-eight DE-circRNAs were upregulated, whereas twenty-seven DE-circRNAs were downregulated in R/R-AML samples. Up-regulated DE-circRNAs in R/R-AML samples were mainly enrichment in the biological processes and pathways of cell migration, microRNAs in cancers, Rap1 and Ras signaling pathways. Six DE-circRNAs were randomly selected to further explore their relationships with R/R-AML. GO and KEGG pathway analyses of the six candidate DE-circRNAs-related target mRNAs were mainly involved in the regulation of signal transduction and Ras signaling pathway. By overlapping our RNA-sequencing results of differentially expressed genes (DEGs) in R/R-AML samples with the candidate DE-circRNAs-predicted target mRNAs, we identified sixty-eight overlapping targeted mRNAs. Using UALCAN database analysis, we identified that AML patients with six upregulated DE-circRNA-related genes (ECE1, PI4K2A, SLC9A6, CCND3, PPP1R16B, and TRIM32) and one downregulated gene DE-circRNA-related genes (ARHGAP10) might have a poor prognosis.
This study revealed the overall alterations of circRNAs in R/R-AML. DE-circRNAs and their related genes might be used as potential early, sensitive and stable biomarkers for AML diagnosis, R/R-AML monitoring, and even as novel treatment targets for R/R-AML.
复发/难治性急性髓系白血病(R/R-AML)由于化疗耐药,预后不佳。环状RNA(circRNA)在包括血液系统恶性肿瘤在内的多种癌症的化疗耐药中发挥着越来越重要的作用。然而,circRNA在AML进展和耐药中的潜在作用仍 largely未确定。
在本研究中,使用人circRNA阵列分析了R/R-AML、AML和健康对照(HC)之间的循环circRNA表达谱。进行生物信息学分析以探索差异表达的circRNA(DE-circRNA)。进行了GO、KEGG通路分析以及circRNA-miRNA-mRNA网络分析,以确定R/R-AML中潜在的生物学通路。最后,使用UALCAN数据库评估不同靶标DE-circRNA相关mRNA的预后。
在R/R-AML样本中,48个DE-circRNA上调,而27个DE-circRNA下调。R/R-AML样本中上调的DE-circRNA主要富集于细胞迁移、癌症中的微小RNA、Rap1和Ras信号通路的生物学过程和通路。随机选择6个DE-circRNA以进一步探索它们与R/R-AML的关系。对6个候选DE-circRNA相关靶标mRNA的GO和KEGG通路分析主要涉及信号转导和Ras信号通路的调节。通过将我们在R/R-AML样本中差异表达基因(DEG)的RNA测序结果与候选DE-circRNA预测的靶标mRNA进行重叠,我们鉴定出68个重叠的靶标mRNA。使用UALCAN数据库分析,我们确定,具有6个上调的DE-circRNA相关基因(ECE1、PI4K2A、SLC9A6、CCND3、PPP1R16B和TRIM32)和1个下调的基因DE-circRNA相关基因(ARHGAP10)的AML患者可能预后不良。
本研究揭示了R/R-AML中circRNA的总体变化。DE-circRNA及其相关基因可能用作AML诊断、R/R-AML监测的潜在早期、敏感和稳定生物标志物,甚至可作为R/R-AML的新型治疗靶点。